| 股票名称 | 回购数 | 回购额 | 年累计回购数量(股) | 年累计回购数量/总 | | --- | --- | --- | --- | --- | | | | | | 股本 | | 腾讯控股(00700) | 86.60 万 | 5.50 亿 | 5388.40 万 | 0.586% | | 恒生银行(00011) | 21.00 万 | 2481.71 万 | 591.00 万 | 0.314% | | 中国宏桥(01378) | 98.00 万 | 2373.63 万 | 1.49 亿 | 1.590% | | 美高梅中国(02282) | 100.00 万 | 1608.69 万 | 1762.74 万 | 0.464% | | 中集集团(02039) | 74.29 万 | 592.84 万 | 1124.07 万 | 0.360% | | 中旭未来(09890) | 37.66 万 | 577.54 万 | 490.44 万 | 0.920% | | 威高股份(01066) | 72.00 万 | 408.78 万 | 1002.40 万 | 2.220% | | 蒙牛乳业(02319) | ...

智通财经APP讯，普华和顺(01358)发布公告，于2025年9月10日该公司斥资67.5万港元回购45万股，回 购价格为每股1.5港元。 该信息由智通财经网提供 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 普华和顺集团公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年9月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01358 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存 ...

格隆汇9月9日丨普华和顺(01358.HK)公告，9月9日耗资88.8万港元回购60万股。 ...

智通财经APP讯，普华和顺(01358)发布公告，于2025年9月9日该公司斥资88.8万港元回购60万股，回购 价格为每股1.48港元。 ...

普华和顺(01358)发布公告，于2025年9月9日该公司斥资88.8万港元回购60万股，回购价格为每股1.48港 元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 1). | 購回以作註銷但尚未註銷之股份 | | 3,200,000 | 0.2159 % | HKD | 1.428 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2025年9月1日 | | | | | | 2). | 購回以作註銷但尚未註銷之股份 | | 460,000 | 0.031 % | HKD | 1.401 | | | 變動日期 | 2025年9月2日 | | | | | | 3). | 購回以作註銷但尚未註銷之股份 | | 660,000 | 0.0445 % | HKD | 1.399 | | | 變動日期 | 2025年9月3日 | | | | | | 4). | 購回以作註銷但尚未註銷之股份 | | 674,000 | 0.0455 % | HKD | 1.392 | | | 變動日期 | 2025年9月4日 | | | | | | 5). | 購回以作註銷但尚未註銷之股份 | | 788,000 | 0.05 ...

Group 1 - The article reports on stock buybacks conducted by various companies on September 5, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent [1][2] - Tencent Holdings repurchased 913,000 shares for a total of 551 million, representing 0.558% of its total share capital [2] - Other notable companies involved in buybacks include China Hongqiao (01378) with 1.276 million shares repurchased for 31.57 million, and Midea Group (N23078) with 300,000 shares for 25.83 million [2] Group 2 - The total number of shares repurchased by China Hongqiao reached 146 million, accounting for 1.560% of its total share capital [2] - Midea Group's cumulative buyback for the year stands at 863,400 shares, which is 0.133% of its total share capital [2] - Other companies such as Yum China (09987) and MGM China (02282) also participated, with Yum China repurchasing 57,700 shares for 20.13 million and MGM China repurchasing 1 million shares for 15.78 million [2]

Core Viewpoint - Puhua Heshun (HK1358) reported a total revenue of 414.4 million RMB for the first half of 2025, reflecting a year-on-year growth of 22.4%, while net profit decreased by 7.5% to 86.6 million RMB, indicating a complex operational environment influenced by industry reforms and competition [3][4][13]. Group 1: Business Performance - The blood purification segment generated 297.4 million RMB in sales, marking a significant increase of 44.5% year-on-year, driven by unmet market demand and an increase in end-stage renal disease (ESRD) patients [3][5][6]. - The infusion device segment reported revenues of 113.4 million RMB, down 14.5% year-on-year, primarily due to the impact of volume-based procurement policies and intensified market competition [8][9]. - The regenerative medical biomaterials segment achieved its first revenue of 3.54 million RMB, indicating a transition from R&D to market introduction [3][9][10]. Group 2: Market Dynamics - The Chinese medical device market is experiencing rapid growth, particularly in blood purification, with an estimated 3.5 million ESRD patients by 2024, representing 30% of the global total, but with a treatment rate below 20% [5][6]. - The number of blood dialysis centers in China has increased to 8,456, reflecting the expansion of dialysis services [5]. - Puhua Heshun's blood purification business accounted for 71.8% of total revenue in the first half of 2025, highlighting its market leadership [5][6]. Group 3: Strategic Initiatives - The company is actively participating in volume-based procurement to stabilize market share, despite the pressure on profit margins [6][7]. - Puhua Heshun is expanding both domestic and international markets, with significant sales growth in regions like India, the Americas, and Africa, although initial export margins are lower [7][8]. - The company is enhancing its product portfolio in blood purification, maintaining a leading position in consumables while also expanding into equipment sales [7][8]. Group 4: R&D and Innovation - R&D expenditure increased by 9.2% to approximately 225 million RMB in the first half of 2025, focusing on the three core business areas [11][12]. - The company has submitted multiple product registration applications, including for blood purification devices and aesthetic medical products, indicating a robust pipeline for future growth [11][12]. - As of June 30, 2025, Puhua Heshun holds 58 product registration certificates and 177 patents, showcasing its strengthened R&D capabilities [12]. Group 5: Future Outlook - The blood purification business is expected to continue expanding in both domestic and international markets, enhancing product technology and profitability [14]. - The infusion device segment aims to adapt to volume-based procurement policies and explore new application areas for stable growth [14]. - The regenerative medical biomaterials segment is poised to accelerate new product launches, potentially becoming a new growth engine for the company [14].

Group 1 - The company, PwC and Shun (01358.HK), announced a share buyback on September 5, spending HKD 1.103 million to repurchase 788,000 shares [1] - On September 4, the company spent HKD 938,100 to buy back 674,000 shares [1]